dichlororibofuranosylbenzimidazole has been researched along with Astrocytoma, Grade IV in 2 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dixit, D | 1 |
| Sharma, V | 1 |
| Ghosh, S | 1 |
| Mehta, VS | 1 |
| Sen, E | 1 |
| Desbaillets, I | 1 |
| Diserens, AC | 1 |
| de Tribolet, N | 1 |
| Hamou, MF | 1 |
| Van Meir, EG | 1 |
2 other studies available for dichlororibofuranosylbenzimidazole and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
Topics: Apigenin; Apoptosis; Brain; Brain Neoplasms; Casein Kinase II; Cell Cycle Checkpoints; Cell Line, Tu | 2012 |
Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma.
Topics: Animals; Cell Hypoxia; Cobalt; Dactinomycin; Dichlororibofuranosylbenzimidazole; Endothelial Growth | 1999 |